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Text: Background 
The UK CF registry analysis showed that people with prior high levels of rescue will often continue to need high levels of 
rescue. We hypothesised that low preventative nebuliser adherence is an important predictor for rescue IV use. The UK CF 
registry does not record adherence data. We therefore analyse I-neb® adherence data alongside IV use data from the 
Sheffield Adult CF centre. 
 
Methods 
2EMHFWLYHDGKHUHQFHZDVFDOFXODWHGIRUWKRVHZLWKPRQWKVRI,-neb® data. Those on ivacaftor were excluded. A tree-based 
method (Zhang & Bracken, AJE 1996) was used to divide the study sample into clinically meaningful subgroups based on 
results of the UK CF registry analysis. For each subgroup, IV use in 2013 & 2014 are compared among those with adherence 
YV7KLVFXW-off for ´good adherence´ was based on previous studies. 
 
Results 
For each clinical subgroup, people with good adherence tend to need fewer IV. 
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One way 
ANOVA 
(comparing 
across the 
8 groups) 
p-value 
2013: 
number of 
adults with 
CF 
7 32 1 16 1 8 1 24   
2013: IV 
days, mean 
(SD) 
3.0 (5.5) 13.3 (13.4) 14 ** 44.0 (25.3) 0 ** 13.8 (18.3) 28 ** 47.5 (38.5) < 0.001 
2013: IV 
days, 
median 
(IQR) 
0 (0-7) 14 (0-26) 14 ** 43 (17-69) 0 ** 13 (0-14) 28 ** 28 (14-64)   
2014: 
number of 
adults with 
CF 
10 23 1 21 2 12 1 18   
2014: IV 
days, mean 
(SD) 
8.0 (11.9) 10.4 (12.1) 35 ** 30.3 (22.5) 7.0 (9.9) 23.4 (22.2) 14 ** 46.5 (34.7) < 0.001 
2014: IV 
days, 
median 
(IQR) 
0 (0-15) 10 (0-14) 35 ** 25 (14-47) 7 ** 16 (14-32) 14 ** 41 (14-70)   
[IV use by group **Unable to calculate SD /  IQR] 
 
Those with worsening FEV1 / increasing IV days resulting in worsening of their clinical subgroup from 2013 to 2014 (n=16) 
have lower adherence in 2013 compared to those who remained stable / improved (n=71); mean 22% (95% CI 12-33%) vs 
40% (95% CI 33-47%), p-value 0.007. 
 
Conclusion 
Nebuliser adherence is an important modifiable risk factor for high IV use. Those with high IV use may benefit from better 
nebuliser adherence. 
 
